Compare RDY & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDY | CFR |
|---|---|---|
| Founded | 1984 | 1868 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 10.0B |
| IPO Year | 2001 | 1994 |
| Metric | RDY | CFR |
|---|---|---|
| Price | $12.18 | $158.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 13 |
| Target Price | $16.90 | ★ $142.31 |
| AVG Volume (30 Days) | ★ 2.3M | 468.8K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | 0.52% | ★ 2.80% |
| EPS Growth | N/A | ★ 11.84 |
| EPS | N/A | ★ 5.35 |
| Revenue | N/A | ★ $2,235,244,000.00 |
| Revenue This Year | $7.72 | $9.72 |
| Revenue Next Year | $3.50 | $4.70 |
| P/E Ratio | ★ $18.67 | $30.07 |
| Revenue Growth | N/A | ★ 8.31 |
| 52 Week Low | $11.36 | $119.00 |
| 52 Week High | $15.67 | $170.80 |
| Indicator | RDY | CFR |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 36.01 |
| Support Level | $11.99 | $152.19 |
| Resistance Level | $12.38 | $163.81 |
| Average True Range (ATR) | 0.16 | 2.84 |
| MACD | 0.03 | -1.18 |
| Stochastic Oscillator | 32.69 | 0.66 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Cullen/Frost is a regional US bank with around $54 billion in assets (as of June 2026), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based banking approach that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through targeted branch openings rather than acquisitions. The bank's sweet spot is small to medium-sized Texas-based commercial clients.